Ximeets

[chris macrae]

1/27 UK Starmer 4 day trip to beijing with 50 companies weekend in Japan))

Grok reported 10 collab items mou'd between xi , starmer and 50 leaders accompanying starmer; more deeply we will search through joint interests in the 10 items by commonwealth englisah and other leaders (eg macron, carney french commonwealth), japan commonwealth- we review how open ai models can scale next generational intelligence collaborations (ie transform purpose of intelligence education)

1. Healthcare/Medicine/Pharmaceuticals — Expanded cooperation in health services, joint research, and commercial applications (e.g., AstraZeneca's $15 billion investment in Chinese manufacturing, R&D, and new medicines through 2030).
2. Finance/Financial Services — Deeper ties in banking, insurance, capital markets, and cross-border financial innovation (e.g., frameworks for market access, RMB business, and data sharing/supervision between regulators like the UK's FCA and China's NFRA).
3. Education and Skills — Win-win partnerships in education, including technical/vocational education and training (TVET) collaboration.
4. Artificial Intelligence (AI) Research — Joint research and applications in AI.
5. Life Sciences/Biotechnology — Shared research and commercial development.
6. New Energy and Low-Carbon Technologies — Cooperation on clean energy, green transformation, and sustainable tech.
7. Services Sector (Broader) — Mutual beneficial expansion in services, including professional services, legal services, and a bilateral services partnership/feasibility study for negotiations.
8. Trade and Investment — Greater market access, reduced barriers (e.g., halved tariffs on Scotch whisky from 10% to 5%, boosting UK exports by ~£250 million over five years), and support for British firms in China.
9. People-to-People Exchanges and Travel — Enhanced facilitation, including 30-day visa-free access for British citizens (aligning the UK with ~50 other countries) and increased cultural/tourism ties.
10. Other Specific Areas — Includes conformity assessment, exports from the UK to China, strengthening the UK-China Joint Economic and Trade Commission, domiciliary services and sports industries, and cooperation on transnational organized crime/irregular migration (e.g., disrupting smuggling networks and supply chains for small boat engines).

Tarif world - Bloomberg layout nice but pay for https://www.bloomberg.com/graphics/trump-tariffs-tracker/

Presumably this is raw resource of every us change https://www.whitehouse.gov/presidential-actions/

Oregon summary interesting but not compete? https://www.oiaglobal.com/tariff-updates/

Beyond Russia and N Korea, data thats now absolutely critical (eg if uniting nations is still a thing) very interesting to be aware of who meets XI and any published agreements. We can time these as post december 2025 (ie Venezuela) intervention or post Jan 2025 (ie Trump2.0)

Post dec 2025

S korea Leader

Canadian leader Carney

French leader macron

Trump scheduled April 2026

Chinese relationship very interesting with

Brazil

India

...Please ntye except where alternatively credited we have relied on Grok for the commentaries below

Further notes UAE

[chris macrae]

Korea S

Grok - 

• South Korean President Lee Jae-myung: He arrived in Beijing on January 4, 2026, for a four-day state visit and met Xi on January 5. This was his first visit to China since taking office in June 2025 and the first by a South Korean president in over six years (since 2019). The leaders discussed restoring and upgrading bilateral ties, economic cooperation (including supply chains, tourism, and business forums with over 200 South Korean executives), regional security, and cultural exchanges (e.g., gradually lifting restrictions on Korean pop culture). Lee described the summit as a "turning point" for making 2026 the year of full restoration of relations, while Xi emphasized mutual respect and win-win outcomes.

also note originally there was a trilateral scheduled for january between china korea s and Japan but ...

[chris macrae]

Canada

Canada has a high-level visit scheduled very soon. Canadian Prime Minister Mark Carney is set to arrive in Beijing for a five-day state visit starting January 13–17, 2026 (just days from the current date of January 9, 2026). This will be the first visit by a Canadian prime minister to China in nearly a decade (since Justin Trudeau's in 2017).

• Carney is expected to meet President Xi Jinping, Premier Li Qiang, and other senior officials and business leaders.
• Key topics include trade diversification (amid deteriorating U.S.-Canada ties due to tariffs), energy, agriculture, international security, climate change, and basic manufacturing.
• The visit aims to thaw relations, which have been strained since 2018 (e.g., Huawei executive arrest, arbitrary detentions, and recent tariffs on electric vehicles/steel).

No Canadian leader has visited Beijing to meet Xi since January 2025; the last high-level in-person contact was in October 2025 on the sidelines of an event in South Korea.Sources: Reports from Macao News Agency (Jan 8, 2026), Anadolu Agency, The Straits Times (Jan 7, 2026), National Observer (Jan 7, 2026), and POLITICO (Jan 7, 2026).

[chris macrae]

Brazil

Brazil and China indeed have extensive mutual investments, with China as Brazil's largest trading partner (bilateral trade hit record levels around $180 billion in recent years). Ties have deepened significantly under President Luiz Inácio Lula da Silva, focusing on diversification beyond commodities into green energy, infrastructure, manufacturing, AI, and sustainable development.Key documented developments in 2025–2026:

• May 2025 state visit by Lula to Beijing: Lula met Xi Jinping on May 13, 2025, during a China-CELAC Forum. They signed multiple cooperation documents in AI, new energy, infrastructure, pharmaceuticals, aerospace, fiscal/financial affairs, and development strategy alignment. Emphasis on Belt and Road synergy, energy transition, and digital economy.
• $1 billion bilateral investment fund (announced October 2025, operations starting 2026): Jointly funded by Brazil's BNDES (~$400 million) and China's Export-Import Bank. Targets energy transition, infrastructure, agriculture, mining, and AI.
• 2025–2026 Action Plan for Sustainable Mining: Attracts investments in low-carbon technologies and responsible resource management.
• Major projects: BYD's new EV factory in Brazil (fully operational by end-2026); bi-oceanic railway corridor (announced July 2025 at BRICS Summit in Brazil); increased Chinese investments in green energy, telecommunications, and reforestation/carbon capture.
• Broader context: Trade is evolving, with manufacturing exports to China rising (23% in Q1 2025). Cooperation via BRICS (Brazil hosted 2025 summit) and New Development Bank.

Further notes:

This Euss Wilcox intelligence on China and Brazil after Venezuela intervention is extraordinary https://substack.com/home/post/p-184017781 To be transparent I have met Russ twice at UN and in DC; he has a very deep llm methodology but what happens next is still to be verified!

[chris macrae]

India

Indian Prime Minister Narendra Modi met Chinese President Xi Jinping within the last 12 months (from January 9, 2025, to January 9, 2026).

• The most recent meeting was on August 31, 2025, in Tianjin, China, on the sidelines of the Shanghai Cooperation Organisation (SCO) Summit. This was Modi's first visit to China in seven years. The leaders held a bilateral discussion lasting over 50 minutes, reviewing progress in India-China relations since their previous encounter, emphasizing peace and tranquility along the border as essential for ties, mutual trust/respect/sensitivity, and cooperation in multilateral forums. Modi invited Xi to the 2026 BRICS Summit in India (which Xi accepted in principle, offering support for India's presidency). They also discussed resuming direct flights and broader normalization post-2020 border tensions.

Prior to that they met in October 2024 at the BRICS Summit in Kazan, Russia, marking their first structured bilateral in five years. Sources: Official readouts from India's Ministry of External Affairs, China's Foreign Ministry, reports from The Hindu, NPR, BBC, Reuters, Hindustan Times, and The Diplomat (August–September 2025 coverage).

[chris macrae]

Trump April 2026

• U.S. President Donald Trump: Scheduled to visit Beijing in April 2026 to meet Xi. This follows their November 2025 phone call and October 2025 meeting in South Korea, where they discussed trade de-escalation, Taiwan, and Ukraine. The visit aims to continue stabilizing U.S.-China relations, with reciprocal hosting later in 2026.

[chris macrae]

UAE  UAE President Sheikh Mohamed bin Zayed Al Nahyan and Xi Jinping 

last meeting was in May 2024, during Sheikh Mohamed's state visit to Beijing. They held talks at the Great Hall of the People, signed agreements on investment, economy, AI, and sustainable development, and attended the China-Arab States Cooperation Forum. This marked the 40th anniversary of diplomatic ties and elevated their comprehensive strategic partnership.

Subsequent high-level engagements (e.g., Chinese Foreign Minister Wang Yi's visit to UAE in December 2025) referenced implementing the 2024 understandings but did not involve a leader-level Xi-MBZ meeting.No upcoming visits or meetings in Beijing (or elsewhere) are reported for the UAE leader in early 2026.Sources: UAE Ministry of Foreign Affairs, China's Ministry of Foreign Affairs readouts, The National (UAE), Reuters, and Wam (December 2025 joint statements).These patterns align with China's broader diplomacy: deepening ties with India amid border stabilization and Global South alignment, while maintaining strong economic partnerships with Gulf states like the UAE without recent summit-level resets

[chris macrae]

https://www.chinaconference.asia/agenda?CMCampaignID=e9a029f52e94ed...

scsp (hk news) annual china summit - feb 2026 cohosted with Indonesia

Tue Feb 10

8:00 AM

8:00 AM - 9:00 AM GMT +7 / Mon Feb 09, 8:00 PM - 9:00 PM Your local time   (1 Hour)

Registration

9:00 AM

9:00 AM - 9:05 AM GMT +7 / Mon Feb 09, 9:00 PM - 9:05 PM Your local time   (5 Min)

Welcome Remarks

Tammy Tam

Publisher

South China Morning Post

Speaker

9:05 AM

9:05 AM - 9:55 AM GMT +7 / Mon Feb 09, 9:05 PM - 9:55 PM Your local time   (50 Min)

Keynote Sessions

The Hon CY Leung, GBM, GBS, JP, KCM

Vice Chairman

National Committee of the Chinese People's Political Consultative Conference

Keynote

HE Dr (HC) Ir H. Airlangga Hartarto

Coordinating Minister for Economic Affairs

Republic of Indonesia

Keynote

Anindya Novyan Bakrie

Chairman, Indonesia Chamber of Commerce and Industry (KADIN Indonesia)

CEO, Bakrie & Brothers

Keynote

9:50 AM

9:50 AM - 10:20 AM GMT +7 / Mon Feb 09, 9:50 PM - 10:20 PM Your local time   (30 Min)

Leveraging legal reform as an economic catalyst – Insights from Hon...

This session will examine how Indonesia can harness legal reform as a direct engine for growth by drawing on the Hong Kong Special Administrative Region (HKSAR) as both a model and a practical partner, with particular emphasis on sub‑regional development in islands such as Batam, Bintan, Galang, Bangka and Belitung. The discussion will move beyond traditional incentives to look at how liberal, investor‑friendly legal frameworks and special regimes can anchor new growth poles in these islands, building on Indonesia’s own experience with special economic zones and growing public acceptance of such models.

• Explore how Indonesia can turn legal reform into a growth engine, using Hong Kong’s common law-based system as a blueprint to boost investor confidence and FDI

• Gain the insider view on Hong Kong’s real success factors – legal certainty, independent courts and trusted dispute resolution – and how they could translate into Indonesia’s context

• Explore possible opportunities in Batam, Bintan, Galang, Bangka and Belitung as pilot “lab islands” for advanced legal frameworks, special regimes and high-value investment

The Hon Dr Horace Cheung Kwok-kwan, SBS, JP

Deputy Secretary for Justice

Government of the Hong Kong Special Administrative Region

Panelist

10:20 AM

10:20 AM - 10:50 AM GMT +7 / Mon Feb 09, 10:20 PM - 10:50 PM Your local time   (30 Min)

Plenary Panel: Strategic equilibrium – Indonesia’s diplomatic balan...

Indonesia’s “hedging plus” strategy is redefining regional diplomacy as it balances US and China ties, advances new diplomatic frameworks and deepens China-Asean-Indonesia trilateral cooperation. This panel will examine how Indonesia’s engagement with the evolving Belt & Road Initiative aligns with Asean priorities and enhances its role as a mediator, while exploring how diplomatic innovation can reinforce stability and position Indonesia at the heart of a more connected and resilient Southeast Asia.

• How can trilateral China-Asean-Indonesia relationships strengthen regional unity and Indonesia’s diplomatic influence?

• In what ways does Indonesia’s evolving Belt & Road participation shape its foreign policy and regional partnerships?

• How can new diplomatic frameworks like the 2+2 Dialogue help Indonesia navigate great-power rivalry and set regional norms?

• What lessons can Asean draw from Indonesia’s approach to balancing strategic autonomy with economic engagement?

Mohamed Amersi

Chairman

Amersi Foundation

Panelist

Bernardino Moningka Vega

CEO, AdaKami

Vice Chairman of Foreign Affairs, Indonesia Chamber of Commerce and Industry (KADIN Indonesia);

Panelist

10:50 AM

10:50 AM - 11:20 AM GMT +7 / Mon Feb 09, 10:50 PM - 11:20 PM Your local time   (30 Min)

Networking Break

11:20 AM

11:20 AM - 11:50 AM GMT +7 / Mon Feb 09, 11:20 PM - 11:50 PM Your local time   (30 Min)

Indonesia and the future of China+1 – Navigating opportunities and ...

Indonesia is emerging as a leader in post-pandemic supply chain innovation and logistics connectivity, leveraging new momentum behind the Belt & Road Initiative to upgrade infrastructure and attract diversified FDI. This panel will explore how enhanced China-Asean-Indonesia economic corridors – and a new focus on Hong Kong-Indonesia investment pathways – can drive capital flows, technology transfer and industrial competitiveness, positioning Indonesia as Southeast Asia’s hub for resilient, future-ready trade networks.

• How can Indonesia lead in supply chain innovation and logistics to secure its China+1 advantage?

• What new opportunities does the Belt & Road’s evolution offer for Indonesia’s trade and connectivity?

• How can Hong Kong-Indonesia investment corridors accelerate technology transfer and capital inflows to Indonesia?

• What strategies will help Indonesia outpace regional rivals in attracting sustainable, high-quality FDI?

Shinta Widjaja Kamdani

Chief Executive Officer, Sintesa Group

Coordinating Vice Chairwoman for Human Development, Culture, and Sustainable Development, Indonesia Chamber of Commerce and Industry (KADIN Indones...

Panelist

Hu Hang

Global Partner, Fosun

Chairman & CEO, Fosun Health Group

Panelist

Roy Tan

Head, Enterprise Banking International

OCBC Bank

Panelist

11:50 AM

11:50 AM - 12:20 PM GMT +7 / Mon Feb 09, 11:50 PM - Tue Feb 10, 12:20 AM Your local time   (30 Min)

Unlocking capital and digital innovation – The future of financial ...

Indonesia's financial sector is undergoing a profound transformation, driven by technological innovation, a growing fintech ecosystem and national efforts to expand financial inclusion. Strategic partnerships, the rise of fintech, insurtech, peer-to-peer lending platforms, blockchain and other advancements – especially those leveraging Hong Kong-mainland coordination – are enabling new models that combine traditional financial expertise with cutting-edge digital solutions. This panel will explore how these developments are reshaping Indonesia’s financial landscape and creating pathways to more inclusive growth.

• What strategies can be employed to expand financial inclusion for the underbanked and unbanked communities in Indonesia?

• How can fintech and innovative financial solutions empower SMEs and entrepreneurs to drive economic growth?

• What role does blockchain technology and digital currencies play in enhancing transparency and efficiency in financial transactions?

• How can collaboration between traditional financial institutions, insurance, fintech startups, and regulators help navigate challenges and foster innovation?

Binayak Dutta

Senior Managing Director, Southeast Asia & Group Chief Business Operations Officer

FWD

Panelist

Quan Yu

Senior Vice President

Ant International

Panelist

12:20 PM

12:20 PM - 1:00 PM GMT +7 / 12:20 AM - 1:00 AM Your local time   (40 Min)

Building Indonesia’s digital future – AI infrastructure and opportu...

Southeast Asia’s digital transformation is accelerating, with new investment from Chinese tech companies shaping the future of AI infrastructure across the China-Asean corridor. This panel will explore how businesses can capitalise on these advancements by investing in data centers and renewable energy, integrating AI into their operations and fostering innovation to remain competitive. Key topics will include strategies for attracting investment, overcoming challenges and creating sustainable opportunities in the evolving digital economy.

• What is the role of Chinese tech companies in driving AI-driven productivity and innovation in ASEAN and Indonesia?

• What are the key investment opportunities and challenges in Asean and Indonesia?

• What infrastructure investments, such as data centers and renewable energy, are needed to support sustainable digital growth?

• How can Indonesia and Southeast Asian markets leverage FDI into AI infrastructure and the wider innovation economy for long-term competitiveness?

Jo Miyake

Head of Banking, Asia and Middle East, Corporate and Institutional Banking

HSBC

Panelist

Shihong Qian

Chief Strategy Officer

Huawei Indonesia

Panelist

Vikram Sinha

President Director & CEO

Indosat Ooredoo Hutchison

Panelist

Sean Yuan

Vice President, Alibaba Cloud International

General Manager of South Pacific Region, Alibaba Cloud Intelligence Group

Panelist

1:00 PM

1:00 PM - 2:30 PM GMT +7 / 1:00 AM - 2:30 AM Your local time   (1 Hour, 30 Min)

Networking Luncheon

[chris macrae]

summit oart 2 

2:30 PM - 2:45 PM GMT +7 / 2:30 AM - 2:45 AM Your local time   (15 Min)

Afternoon Keynote

2:45 PM - 3:15 PM GMT +7 / 2:45 AM - 3:15 AM Your local time   (30 Min)

Powering progress – Integrating sustainability, innovation and loca...

As Indonesia positions itself as a global leader in clean energy transition and sustainable agricultural practices, this panel will explore how innovative strategies and emerging technologies, such as AI, are reshaping supply chains to address business challenges while balancing environmental, social, and economic goals. The discussion will highlight how technology can amplify industrial knowledge, drive sustainable growth, and transition from auxiliary applications to core systems, ensuring long-term impact and innovation.

• How can Indonesia leverage its leadership in clean energy and agriculture to set new benchmarks for sustainable, technology-driven supply chains?

• What conditions are needed for AI to transition from supporting roles to becoming central to supply chain operations?

• How can technologies like AI amplify industrial knowledge and enable sustainable growth while addressing supply chain challenges?

• What role do public-private-community partnerships and carbon markets play in advancing Indonesia’s climate and sustainability goals?

Iman Rachman

President Director

IDX

Panelist

Andy Wu

President of Mining BU

Huawei

Panelist

3:15 PM

3:15 PM - 3:45 PM GMT +7 / 3:15 AM - 3:45 AM Your local time   (30 Min)

Patient capital for shared prosperity – How sovereign wealth funds ...

This high-level panel brings together leading figures from  sovereign wealth funds and private capital firms to debate the transformational role of “patient capital.” Panellists will discuss how their institutions drive long-term strategies for infrastructure, technology and inclusive growth, and examine regional collaboration and governance best practices. Delegates gain unique insights into how sovereign wealth funds are building pathways to shared prosperity across Southeast Asia in an era of accelerated global change.

• How does patient capital support infrastructure, energy and technology for long-term development?

• What strategies can balance financial returns with inclusive national growth?

• What regional opportunities exist for co-investment and collaboration in Asean and with China?

• How do governance, transparency and accountability frameworks shape fund mandates?

Jason Chen

Chief Operating Officer & Managing Director

Gobi Partners

Panelist

Pandu Sjahrir

Chief Investment Officer

Danantara Indonesia

Panelist

Daniel Fung, SBS, SC, KC, JP

Vice-Chairman

Financial Services Development Council

Moderator

3:45 PM

3:45 PM - 4:15 PM GMT +7 / 3:45 AM - 4:15 AM Your local time   (30 Min)

Networking coffee break

4:15 PM

4:15 PM - 4:45 PM GMT +7 / 4:15 AM - 4:45 AM Your local time   (30 Min)

China-ASEAN dialogue – Advancing economic synergy for Southeast Asia

This exclusive dialogue will bring together top voices from China and Southeast Asia to discuss the next phase of economic partnership between the regions. The conversation will focus on aligning energy transition leadership with regional priorities, unlocking cross-border sustainable finance and fostering innovative investment models that drive SDG outcomes. Special attention will be paid to scalable collaborations that can serve as regional models and to integrating carbon market and sustainability strategies into bilateral and Asean-wide agendas.

• How can China and Southeast Asia align their energy transition goals to reinforce ASEAN’s sustainable growth?

• What new mechanisms are needed for sustainable financing and SDG-linked investments across borders?

• How can both countries scale up landscape-level partnerships for inclusive and resilient development?

• What lessons from Indonesia’s carbon markets and sustainability efforts can shape broader regional strategies?

Anindya Novyan Bakrie

Chairman, Indonesia Chamber of Commerce and Industry (KADIN Indonesia)

CEO, Bakrie & Brothers

Panelist

Dr Rocky Tung

Executive Director (Designate)

Financial Services Development Council

Panelist

YB Tengku Zafrul Aziz

Chairman

Malaysian Investment Development Authority (MIDA)

Panelist

4:45 PM

4:45 PM - 5:30 PM GMT +7 / 4:45 AM - 5:30 AM Your local time   (45 Min)

Closing Keynote Sessions

The Hon John KC Lee, GBM, SBS, PDSM, PMSM

Chief Executive

Government of the Hong Kong Special Administrative Region

Keynote

Wed Feb 11

8:00 AM - 12:00 PM GMT +7 / Tue Feb 10, 8:00 PM - Wed Feb 11, 12:00 AM Your local time   (4 Hours)

Breakfast Briefing – Doing Business in Indonesia (By Invitation Only)

9:00 AM - 9:10 AM GMT +7 / Tue Feb 10, 9:00 PM - 9:10 PM Your local time   (10 Min)

Welcome remarks by SCMP

9:05 AM - 9:20 AM GMT +7 / Tue Feb 10, 9:05 PM - 9:20 PM Your local time   (15 Min)

Opening remarks

The Hon Dr Horace Cheung Kwok-kwan, SBS, JP

Deputy Secretary for Justice

Government of the Hong Kong Special Administrative Region

Speaker

9:20 AM - 9:50 AM GMT +7 / Tue Feb 10, 9:20 PM - 9:50 PM Your local time   (30 Min)

Policy and market briefing – Entering Indonesia in 2026

This session will provide an in-depth overview of Indonesia’s current economic landscape and market entry opportunities for 2026 and beyond. Learn about recent policy developments, trade agreements, and government initiatives aimed at attracting foreign investment. This briefing will help attendees understand the macroeconomic conditions and strategic sectors primed for growth in Indonesia.

9:50 AM

9:50 AM - 10:10 AM GMT +7 / Tue Feb 10, 9:50 PM - 10:10 PM Your local time   (20 Min)

Legal and regulatory essentials for market entry

Entering a new market requires navigating complex legal and regulatory frameworks. This session will highlight the key legal considerations, compliance requirements, and regulatory processes for establishing and operating a business in Indonesia. Attendees will gain clarity on licensing, tax structures, foreign ownership rules and other critical aspects of doing business.

10:10 AM

10:10 AM - 10:30 AM GMT +7 / Tue Feb 10, 10:10 PM - 10:30 PM Your local time   (20 Min)

Sector spotlight – Industrial parks, localisation and incentives

This session will explore Indonesia’s most promising sectors for foreign investment and growth in areas that could include manufacturing, digital technology, renewable energy and infrastructure. Experts will provide insights into how businesses can tap into these industries, supported by government incentives and development plans. Learn about the trends driving innovation, the competitive advantages Indonesia offers, and how to position your business to capitalize on these opportunities effectively.

10:30 AM

10:30 AM - 11:00 AM GMT +7 / Tue Feb 10, 10:30 PM - 11:00 PM Your local time   (30 Min)

Networking break

11:00 AM

11:00 AM - 11:30 AM GMT +7 / Tue Feb 10, 11:00 PM - 11:30 PM Your local time   (30 Min)

Case studies – Cross-border expansion in Indonesia

Learn from real-world success stories of organisations that have successfully expanded to Indonesia. This session will showcase practical examples of overcoming challenges, building partnerships, and achieving growth in the Indonesian market. Attendees will gain actionable insights from the experiences of seasoned business leaders.

[chris macrae]

Health ai jan 2026 one of uk's biggest investments in china (ai quarter 2) announced by Astra Zeneca - we asked grok to home in on ai health area that astra zeneca and china might map most data on - it chose cancer (do you agree); here's where round 1 questions to grok led- what deeper questions would you ask [e-mail]

Yes, AstraZeneca has connections involving partnerships or collaborations linked to Jensen Huang (CEO of NVIDIA), primarily through NVIDIA's initiatives.

AstraZeneca has longstanding collaborations with NVIDIA (the company Jensen Huang founded and leads) focused on AI for drug discovery and accelerated computing. Key examples include: A 2021 collaboration where NVIDIA and AstraZeneca developed transformer-based generative AI models (like MegaMolBART) for chemical structures in drug discovery, trained on NVIDIA supercomputing infrastructure. AstraZeneca's involvement in NVIDIA's Cambridge-1 supercomputer project in the UK (launched 2021) for healthcare and AI research, including drug design. More recently, in May 2025, a major Swedish business consortium—including AstraZeneca, Ericsson, Saab, SEB, and Wallenberg Investments—partnered with NVIDIA to build Sweden's largest enterprise AI supercomputer (using NVIDIA's Grace Blackwell GB300 systems). This initiative was announced during Jensen Huang's visit to Sweden, where he received an honorary doctorate and discussed the project publicly with Marcus Wallenberg. Huang commented on it as part of building AI infrastructure for breakthroughs in science and industry, with AstraZeneca specifically planning to use it for advanced AI-enabled drug discovery (e.g., foundation model training and multi-modal inference).This positions AstraZeneca as part of a broader NVIDIA-led ecosystem that Jensen Huang has championed and directly promoted.

(check nvidia clara compass - huangs name for all biohealth partners for good) ; check when honk kong and huang announce digital twining world calss cities training hospirals - is cancer data a lead purpose

There is no intitial evidence of a purely personal or direct bilateral "partnership" between AstraZeneca and Huang himself outside his role at NVIDIA, but the company's ties to NVIDIA (and Huang's visible involvement in key announcements) are clear and ongoing.These partnerships highlight AstraZeneca's heavy investment in AI to accelerate pharmaceutical R&D, powered by NVIDIA technology. Square profile picture 8 posts 31 web pages Details on MegaMolBART model Pfizer's AI partnerships Ssyra zeneca announced 16 billion investment in China during statmer visit. Is there a disease category that can be winwin astra zeneca China and jensen Searching the web 39 results Yes, AstraZeneca recently announced a major $15 billion (approximately £11-12 billion, often rounded in media reports) investment in China through 2030, unveiled during UK Prime Minister Keir Starmer's visit to Beijing on January 29, 2026. This is AstraZeneca's largest-ever commitment in China, focusing on expanding medicines manufacturing, R&D capabilities, and accelerating innovative treatments for Chinese patients and globally. It aligns with AstraZeneca's 2030 ambition to deliver transformative medicines and strengthens China-UK healthcare collaboration.A promising win-win disease category for AstraZeneca in China (leveraging this investment) and involving Jensen Huang/NVIDIA (via their ongoing AI partnerships) is oncology (cancer). Why Oncology Fits as a Win-Win AstraZeneca's Strengths in China: China has one of the world's highest cancer burdens, with rising incidence of lung, liver, gastric, and other cancers. AstraZeneca is already a leader in oncology there (e.g., Tagrisso for lung cancer, Imfinzi, Enhertu via partnerships). The new investment explicitly boosts capabilities in advanced areas like cell therapies and radioconjugates (e.g., antibody-drug conjugates for targeted cancer treatment), which are high-priority for addressing unmet needs in China's patient population. This supports faster local development, manufacturing, and access to innovative cancer drugs. NVIDIA/Jensen Huang Angle: AstraZeneca has deep, long-standing collaborations with NVIDIA (led by Jensen Huang) on AI-accelerated drug discovery, including generative AI models for molecule design (e.g., MegaMolBART) and foundation models for multi-modal data in oncology. NVIDIA's platforms power AstraZeneca's AI efforts in simulating drug interactions, predicting efficacy, and optimizing clinical trials—particularly valuable for complex oncology pipelines. Recent examples include hybrid AI-quantum approaches (with partners like IonQ on NVIDIA tech) for drug design in cancer-related applications. A synergistic opportunity could emerge if AstraZeneca deploys NVIDIA-powered AI infrastructure in its expanded China R&D footprint (e.g., for training large-scale oncology foundation models on Chinese patient data, accelerating personalized cancer therapies). This would benefit: AstraZeneca China: Faster, cost-effective innovation tailored to local epidemiology, supporting the $15B investment's goals. NVIDIA/Jensen Huang: Expanded real-world AI adoption in life sciences within China's massive market, building on Huang's public emphasis on AI's "profound impact" in healthcare (as seen in similar NVIDIA deals like with Eli Lilly). Other strong candidates include respiratory or cardiovascular diseases (also AstraZeneca priorities in China), but oncology stands out for its high innovation potential with AI, massive unmet need in China, and direct ties to NVIDIA's drug discovery tools. No public evidence yet of a specific new China-focused NVIDIA-AstraZeneca oncology project tied to this investment, but the ecosystem alignment makes it highly plausible and mutually beneficial. 39 web pages Explain Tagrisso in detail AI in cardiovascular drugs Explain Tagrisso in detail Searching the web 19 results Tagrisso (generic name: osimertinib) is a prescription oral medication developed and marketed by AstraZeneca. It is a targeted therapy specifically designed for certain types of non-small cell lung cancer (NSCLC) driven by mutations in the epidermal growth factor receptor (EGFR) gene. Tagrisso is widely regarded as a cornerstone treatment in EGFR-mutated NSCLC due to its efficacy, including activity against brain metastases, and its broad approvals across disease stages. What Is Tagrisso and How Does It Work? (Mechanism of Action) Tagrisso is a third-generation, irreversible EGFR tyrosine kinase inhibitor (TKI). EGFR is a protein on the surface of cells that, when mutated in certain ways, can drive uncontrolled cancer cell growth in NSCLC. It selectively and potently inhibits EGFR sensitizing mutations (primarily exon 19 deletions and exon 21 L858R substitutions), which are the most common activating mutations in EGFR-mutated NSCLC. It also targets the T790M acquired resistance mutation, which often develops after treatment with first- or second-generation EGFR TKIs (like erlotinib, gefitinib, or afatinib) and causes resistance to those earlier drugs. Importantly, Tagrisso has lower activity against wild-type (normal) EGFR, which helps reduce some off-target side effects seen with less selective TKIs. A key advantage is its ability to cross the blood-brain barrier (BBB) effectively, as shown in preclinical models and human studies (including PET imaging in healthy volunteers and patients). This makes it particularly useful for patients with central nervous system (CNS) metastases, common in advanced lung cancer. By irreversibly binding to these mutant EGFR forms, Tagrisso blocks downstream signaling pathways that promote cancer cell proliferation, survival, and spread, leading to tumor shrinkage or stabilization. Approved Indications (as of 2026) Tagrisso has multiple FDA-approved uses (and similar approvals globally, including in China, EU, etc.), all requiring confirmation of specific EGFR mutations via an FDA-approved test: Adjuvant therapy after tumor resection (surgery) in early-stage (e.g., IB-IIIA) NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations — to reduce the risk of recurrence. Locally advanced, unresectable Stage III NSCLC (after platinum-based chemoradiation therapy, if disease has not progressed) with the same EGFR mutations (based on the LAURA trial approval in 2024). First-line treatment of metastatic (Stage IV) or locally advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations — either as monotherapy or in combination with pemetrexed and platinum-based chemotherapy (e.g., cisplatin or carboplatin), based on trials like FLAURA and FLAURA2. Treatment of metastatic NSCLC with EGFR T790M mutation-positive disease that has progressed after prior EGFR TKI therapy. These indications make Tagrisso versatile across the NSCLC treatment continuum for eligible patients. Dosage and Administration Standard dose: 80 mg tablet taken orally once daily, with or without food. Available in 40 mg and 80 mg strengths. Treatment continues until disease progression or unacceptable toxicity. Dose adjustments or interruptions may be needed for side effects. Common Side Effects Tagrisso is generally better tolerated than traditional chemotherapy, but it can cause side effects (most are mild to moderate). Common ones include: Diarrhea Rash or acne-like skin issues Dry skin Nail changes (e.g., paronychia) Fatigue Decreased appetite Stomatitis (mouth sores) Cough More serious but less common risks (requiring monitoring): Interstitial lung disease (ILD)/pneumonitis — potentially severe or fatal; symptoms like new/worsening cough, shortness of breath. Cardiomyopathy (heart issues, including reduced ejection fraction or heart failure). QT interval prolongation (heart rhythm changes). Keratitis (eye inflammation). Embryo-fetal toxicity — can cause harm to a fetus; effective contraception is required. Regular monitoring (e.g., ECGs, echocardiograms, lung scans) is recommended. In combination regimens, chemotherapy adds typical chemo-related side effects (e.g., nausea, low blood counts).Tagrisso has transformed outcomes for EGFR-mutated NSCLC, often providing longer progression-free survival, better quality of life, and improved overall survival compared to earlier therapies, especially with its CNS penetration and resistance-targeting design. Always consult a healthcare professional for personalized advice, as treatment decisions depend on individual mutation status, stage, and health factors. For the most current details, refer to official sources like the FDA prescribing information or AstraZeneca's Tagrisso website. 19 web pages Explain FLAURA trial results Compare to other EGFR TKIs  see part 2

[chris macrae]

Does astra zeneca have any related partnerships with johns jopkins Searching the web 28 results Yes, AstraZeneca has several established partnerships and collaborations with Johns Hopkins University (and related entities like Johns Hopkins Medicine, Bloomberg School of Public Health, and Johns Hopkins Tech Ventures). These span research, education/training, startup mentoring, and public health initiatives. Note that many originated through MedImmune (AstraZeneca's biologics arm, acquired in 2007) but continue under the AstraZeneca brand. Key Ongoing or Recent Collaborations Johns Hopkins-AstraZeneca Scholars Program (formerly Johns Hopkins-MedImmune Scholars Program): This is a flagship PhD training program launched around 2016. It prepares graduate students for biopharma careers by combining Johns Hopkins' academic curriculum with hands-on drug discovery and development experience at AstraZeneca. Students have dual mentorship (one supervisor from each institution), translational research coursework, and lab rotations at AstraZeneca facilities. It's described as a "first-of-its-kind" initiative and remains active, with examples of current/ recent scholars working on projects in areas like oncology. Young Health Programme (YHP): Founded in 2010, this global initiative by AstraZeneca partners with the Johns Hopkins Bloomberg School of Public Health (and Plan International) to improve adolescent health. It focuses on prevention, research, and interventions for non-communicable diseases (e.g., mental health, respiratory issues) in young people, with ongoing reports and activities as of 2025. Startup and Innovation Mentoring: AstraZeneca's AZ Exchange program (a startup accelerator/mentorship initiative) partners with Johns Hopkins Tech Ventures. This includes co-mentoring cohorts of early-stage companies, with Johns Hopkins startups participating in AstraZeneca-led programs (e.g., inaugural and subsequent cohorts in 2021 and beyond). It provides expertise in oncology, biopharma, and business development. Historical Research Collaborations: A notable 2013 five-year, $6.5 million agreement between MedImmune/AstraZeneca and Johns Hopkins focused on joint research in areas like cancer and respiratory diseases, enabling knowledge exchange and addressing key scientific questions. While older, it laid groundwork for ongoing ties. Other mentions include indirect links (e.g., AstraZeneca executives or researchers collaborating in broader contexts, or shared involvement in events like case competitions hosted by Johns Hopkins Carey Business School), but the above represent direct, structured partnerships.These collaborations highlight AstraZeneca's strategy of partnering with top academic institutions like Johns Hopkins for talent development, translational research, and innovation in biopharma—particularly in oncology, respiratory, and public health. No major new blockbuster deals appear in very recent (2025-2026) headlines beyond the sustained programs, but the relationships are longstanding and multifaceted. For the latest details, check official sites like hopkinsmedicine.org or astrazeneca.com. 28 web pages Details on Scholars Program impact Pfizer-Johns Hopkins partnerships Details on Scholars Program impact Searching the web 41 results The Johns Hopkins-AstraZeneca Scholars Program (formerly the Johns Hopkins-MedImmune Scholars Program, launched in 2016) is a pioneering joint PhD training initiative between Johns Hopkins University and AstraZeneca. It bridges academia and industry by providing dual mentorship (one supervisor from Johns Hopkins and one from AstraZeneca), translational research coursework, and hands-on lab rotations/internships at AstraZeneca facilities. This equips PhD students with real-world drug discovery and development experience while they complete a traditional Johns Hopkins PhD, preparing them for biopharma careers.As of January 2026, the program remains active and ongoing, with current scholars listed on the official Johns Hopkins site (e.g., in fields like chemical/biomoecular engineering for biotherapeutics production and immunology/oncology for pancreatic cancer research using spatial proteomics). Eligibility is open to PhD students (typically entering 2016 or later) across Johns Hopkins schools, with applications facilitated by identifying co-supervisors and joint thesis projects. Impact and Outcomes While comprehensive aggregated metrics (e.g., exact number of alumni, placement rates, or publications) are not publicly detailed in a single report—likely due to the program's focus on individualized training—the available evidence highlights strong positive impacts in several areas: Career Preparation and Industry Transition: The program explicitly aims to prepare students for biopharma roles by exposing them to industry processes, challenges, and environments. Alumni and participants have transitioned into senior scientist or related positions at AstraZeneca and similar companies. For example, some PhD graduates from related Johns Hopkins labs (with ties to the program ecosystem) have secured roles as Senior Scientists at AstraZeneca, often with awards for their work during training (e.g., poster awards, fellowships in genetics or proteomics). Student testimonials and blog posts describe it as providing "hands-on experience in the biomedical field" and a "unique approach to training" that bridges "books to business," fostering skills in translational research and drug development. Research Contributions and Collaboration: Scholars conduct joint projects that advance biomedical science, particularly in areas like oncology, immunology, biotherapeutics, and cell engineering. Current examples include work on secretory pathway bottlenecks for biotherapeutics, immunosuppressive mechanisms in pancreatic cancer, and computational modeling of antibody-drug conjugates. These efforts contribute to AstraZeneca's pipeline while generating high-quality academic output (e.g., publications, spatial proteomics insights). The collaborative model fosters a "dynamic intellectual community" and enables ambitious, industry-relevant research that might not occur in purely academic settings. Talent Development and Broader Ecosystem Benefits: As a "first-of-its-kind" program in the US, it has built lasting ties between Johns Hopkins and AstraZeneca, supporting talent pipelines for biopharma. Participants gain dual perspectives, enhancing their competitiveness in industry jobs. Related activities (e.g., AstraZeneca case competitions won by Johns Hopkins teams) show how the partnership ecosystem amplifies innovation and commercialization skills. Sustained Success Stories: Participant videos and profiles (e.g., featuring scholars like Natalia Majewska) emphasize the program's role in introducing students to industry realities and building confidence for impactful careers. Alumni have achieved recognitions in academia and industry, with some crediting the program for enabling transitions to roles involving cutting-edge drug discovery. Overall, the program's impact lies in its success as a model for academia-industry collaboration: it produces well-rounded PhD graduates equipped for biopharma leadership, drives translational advancements in key therapeutic areas (e.g., oncology and biologics), and strengthens mutual innovation between the institutions. For the most detailed or personalized alumni outcomes, contacting the program director (Dr. Takashi Tsukamoto) or checking the Johns Hopkins site directly is recommended, as public data focuses more on structure and current participants than exhaustive longitudinal stats. 41 web pages Specific alumni career paths Pfizer-JHU Scholars Program Are any of China leading ai models already concerned with cancer. Around the world who is currently doing most relevant ai open model on cancer uniting commonalities of societies need to see ending cancer as largely a collaboration deep data Searching the web 54 results Yes, several leading Chinese AI models and tools are actively concerned with cancer (oncology), particularly in early detection, diagnosis, and screening. China is advancing rapidly in applying AI to cancer due to its large patient population, extensive medical data, and collaborations between tech giants (e.g., Alibaba, Huawei) and hospitals. These efforts often focus on high-burden cancers like pancreatic, gastric, lung, and others common in China. Leading Chinese AI Models/Tools Focused on Cancer Alibaba DAMO Academy's Models (e.g., DAMO PANDA and GRAPE): These are among the most prominent. DAMO PANDA (Pancreatic Cancer Detection with AI): Detects early pancreatic cancer from routine CT scans, often identifying tumors missed by doctors. It earned FDA Breakthrough Device Designation in 2025 (a first for a Chinese medical AI) and has been deployed in Chinese hospitals for screening. GRAPE (Gastric Cancer Screening): Developed with Zhejiang Cancer Hospital, it identifies early stomach cancer from standard non-contrast CT scans with high sensitivity (85.1% in studies). Trained on ~100,000 scans from multiple centers, it's seen as a game-changer for accessible screening. Huawei's RuiPath: A pathology AI model open-sourced in 2025, trained on over 1 million digital pathology slides from Ruijin Hospital (Shanghai Jiao Tong University affiliate). It targets seven common cancers (e.g., lung, breast, colorectal) to enable faster, more accurate diagnoses, especially in smaller hospitals. Other notable efforts include AI tools from institutions like Shanghai Jiao Tong University (e.g., dried blood drop tests for colorectal, gastric, and pancreatic cancers) and broader applications in lung cancer or multi-cancer detection. These are not general-purpose LLMs like Baidu's Ernie, Alibaba's Qwen, or Huawei's Pangu (which focus on broad capabilities), but specialized models often built or fine-tuned by these companies' research arms (e.g., DAMO Academy, Huawei's Noah's Ark Lab) for oncology. China's AI in oncology market is growing fast (~14% of global share), driven by diagnostics, drug discovery deals (e.g., with AstraZeneca, Pfizer), and tools outperforming humans in specific tasks. Globally, the Most Relevant Open AI Models/Collaborations for Cancer (Uniting Common Needs via Deep Data Collaboration) The push for ending cancer as a collaborative, data-driven effort emphasizes open-source models, federated learning (training across institutions without sharing raw data for privacy), and multimodal foundation models that integrate genomics, imaging, clinical records, etc. This addresses societal needs for equitable access, personalized medicine, and global breakthroughs by pooling diverse datasets while protecting privacy.Key standouts (as of early 2026): Cancer AI Alliance (CAIA): A major U.S.-based collaboration (Johns Hopkins, Dana-Farber, Fred Hutch, Memorial Sloan Kettering) with tech support from AWS, Google, Microsoft, NVIDIA, etc. It launched a scalable, multi-cloud federated learning platform in 2025 for secure AI training on millions of de-identified records across centers. Projects include fine-tuning LLMs on EHR data and studying rare brain cancers (e.g., IDH-mutant gliomas) via multicenter data—directly uniting institutions to accelerate discoveries without centralizing sensitive data. Freenome's Open-Source cfDNA Foundation Model (with NVIDIA): Focuses on cell-free DNA for multi-cancer early detection. They're building and open-sourcing a methylation-focused foundation model using proprietary + public data, enabling broader research into personalized cancer signals. GigaTIME (Microsoft Research, with Providence/University of Washington): An open-source tool on Hugging Face and Azure for modeling tumor microenvironments from pathology slides. Trained on diverse data from >14,000 patients, it maps immune-cancer interactions at scale to predict treatment responses and resistance—publicly available for global researchers. C2S-Scale 27B (Google DeepMind + Yale): A 27-billion-parameter open model (built on Gemma) for single-cell analysis, advancing understanding of cellular "language" in cancers. Other efforts: MONAI (NVIDIA-led open framework for medical imaging AI, applied to oncology screening); federated platforms like those from Duality Technologies (used in Dana-Farber studies). These represent the frontier: collaborative, open, privacy-preserving approaches that treat cancer as a shared global challenge. Federated learning (e.g., CAIA) is particularly relevant for "uniting commonalities" across societies, as it enables deep data insights from diverse populations (e.g., China/U.S./Europe) without borders or privacy risks. No single "most relevant" open model dominates yet, but CAIA's platform and tools like GigaTIME stand out for scale and real-world collaboration potential. Ongoing work in China (e.g., via Alibaba/Huawei open-sourcing pathology models) could integrate into global efforts for even greater impact. 54 web pages Explain federated learning in CAIA AI for drug discovery in oncology Is it possible to match history of astra zeneca as Britain number 1 chemical company with Chinese historic heros in chemistry as well as pharma and biotech Searching the web 37 results Yes, it is possible to draw meaningful parallels between the historical trajectory of AstraZeneca—often positioned as a leading force in Britain's (and Europe's) chemical and pharmaceutical innovation—and key figures in China's long heritage of chemistry, pharmacology, and early biotech-like practices. These connections highlight shared themes of scientific discovery, empirical testing of substances, extraction of active compounds from natural sources, and transforming traditional knowledge into life-saving medicines.AstraZeneca's roots trace back to Britain's industrial chemical legacy, particularly through Zeneca (spun off in 1993 from Imperial Chemical Industries (ICI), formed in 1926 via mergers of major British chemical firms including those tied to Alfred Nobel's explosives). ICI was once Britain's dominant chemical powerhouse, evolving into pharmaceuticals via demergers and the 1999 merger with Sweden's Astra AB to create AstraZeneca. This path reflects Britain's 20th-century shift from broad chemical manufacturing (dyes, explosives, materials) to focused biopharma innovation, emphasizing R&D-driven drug discovery and global impact.China's pharmaceutical heritage spans millennia, rooted in traditional Chinese medicine (TCM)—a system blending empirical observation, herbal pharmacology, and compound isolation—often seen as an early form of "biotech" through systematic herb classification and extraction. Legendary and historical figures embody this, paralleling AstraZeneca's evolution from chemical roots to modern pharma. Key Parallels and Matching Figures Empirical Testing and Risk-Taking for Discovery AstraZeneca/ICI heritage involves systematic chemical synthesis and testing (e.g., from industrial chemicals to targeted drugs like oncology therapies). Shennong (Divine Husbandman, legendary ~2700 BCE): Revered as the "Father of Chinese Medicine" and pharmacology. Myth holds he tasted hundreds of herbs (encountering 70 poisons in one day) to classify them by medicinal properties, authoring an early pharmacopoeia prototype (Shennong Bencao Jing). This mirrors the trial-and-error empirical approach in modern chemistry/pharma, where substances are tested for efficacy and safety—much like AstraZeneca's pipeline development. Comprehensive Compilation and Scientific Classification of Medicines AstraZeneca builds on centuries of chemical knowledge accumulation (e.g., ICI's mergers consolidated British expertise). Li Shizhen (1518–1593, Ming Dynasty): Author of Bencao Gangmu (Compendium of Materia Medica), the most comprehensive TCM encyclopedia, detailing over 1,800 drugs, 1,100 illustrations, and 11,000 prescriptions. He classified substances by type, form, flavor, and application through rigorous observation—akin to modern pharmacological classification and AstraZeneca's evidence-based drug R&D. Modern Extraction of Active Compounds from Traditional Sources AstraZeneca excels in isolating and developing targeted molecules (e.g., Tagrisso/osimertinib from chemical design). Tu Youyou (b. 1930): The most direct modern parallel. A pharmaceutical chemist, she drew from ancient TCM texts (e.g., Ge Hong's ~400 AD references to sweet wormwood/Qinghao for fevers) during Project 523 (1960s–1970s). She isolated artemisinin (qinghaosu) from Artemisia annua, a breakthrough antimalarial that saved millions and earned her China's first science Nobel Prize (Physiology or Medicine, 2015). This bridges TCM heritage with Western-style extraction/purification—similar to how AstraZeneca transforms chemical/biological insights into blockbuster drugs. Other figures like Zhang Zhongjing (Eastern Han, ~150–219 CE, "Chinese Hippocrates" for systematic epidemic treatments) or Sun Simiao (Tang Dynasty, comprehensive medical theories) represent foundational systematization, paralleling Britain's chemical institutionalization (e.g., ICI's scale). Why These Parallels Work in a Broader Context Both histories emphasize innovation from heritage: Britain's via industrial mergers and spin-offs; China's via millennia of herbal empiricism evolving into modern biotech/pharma (e.g., Tu's work as a "fusion" of ancient texts and lab chemistry). Shared goal: Addressing global health crises (e.g., AstraZeneca's oncology/cardio focus; China's malaria breakthroughs via artemisinin). Contemporary ties: AstraZeneca's deep China investments (e.g., $15B+ announced recently) and partnerships build on this legacy, collaborating with Chinese innovators in AI-driven oncology—echoing historical cross-cultural exchanges. In essence, AstraZeneca represents Britain's modern "hero" in chemical-to-pharma evolution, while figures like Shennong, Li Shizhen, and Tu Youyou embody China's enduring "heroes" in pharmacology and compound discovery. Matching them underscores universal scientific progress: from ancient tasting herbs to cutting-edge targeted therapies. 37 web pages Details on Tu Youyou's discovery Parallels with Pfizer's history Does banking university have any strengths in all of above histories.. Searching the web 38 results No, "Banking University" (or similar institutions like Shanghai Lixin University of Accounting and Finance, often associated with banking/finance education in China) does not have notable strengths in the histories of chemistry, pharmacology, pharmaceutical innovation, or biotech as discussed in the context of AstraZeneca's British chemical-to-pharma evolution or China's legendary/heralded figures (e.g., Shennong, Li Shizhen, Tu Youyou). Clarifying "Banking University" In China, there is no single prominent institution officially named "Banking University." The term likely refers to finance/banking-focused schools, such as: Shanghai Lixin University of Accounting and Finance (上海立信会计金融学院, often translated or referred to in contexts involving banking/finance heritage). Origins: Traces to 1928 (accounting roots via Pan Xulun, "Father of Modern Accounting in China") and 1952 (Shanghai Banking School under the People's Bank of China). Evolution: Merged in 2016 from accounting and finance colleges; now emphasizes accounting, finance, auditing, and related economic fields. Strengths: Renowned as a cradle for modern accounting education and future financiers in China; focuses on financial globalization, applied economics, and high-level application-oriented talents in the Yangtze River Delta. Other similar institutions: Shanghai University of Finance and Economics (SUFE), Central University of Finance and Economics (CUFE), Southwestern University of Finance and Economics (SWUFE), etc.—all elite in finance, economics, banking, and related disciplines. These are specialized finance and economics universities, not comprehensive or STEM-heavy ones like Peking University, Tsinghua, Fudan, or Shanghai Jiao Tong, which lead in chemistry, pharmacology, biotech, and pharma-related research. Lack of Strengths in the Relevant Histories No significant programs or historical contributions in chemistry, pharmacology, pharmaceutical sciences, medicinal chemistry, or biotech. Searches for these universities show no rankings, departments, research outputs, or historical ties in QS World University Rankings for Pharmacy & Pharmacology, medicinal chemistry, or related fields. Their focus remains on finance, accounting, banking, economics, international trade, and business—areas that support economic development but do not intersect with empirical herbal pharmacology (like Shennong/Li Shizhen traditions), modern compound isolation (like Tu Youyou's artemisinin work), or industrial chemical/pharma pipelines (like AstraZeneca/ICI's evolution from chemicals to targeted drugs). No evidence of collaborations, research centers, or alumni impacts in oncology, drug discovery, AI-for-cancer, or biotech that align with the prior discussions (e.g., AstraZeneca's oncology focus, Chinese AI models like DAMO PANDA/GRAPE, or global open models like CAIA). In short, while these "banking/finance universities" excel in their domain (cultivating talents for China's financial sector, banks, and economic policy), they have no meaningful overlap or strengths in the chemistry-pharma-biotech histories we've covered. For those areas, China's leaders are institutions like Peking University, Tsinghua (with strong life sciences/biotech), Shanghai Jiao Tong (pathology/AI oncology ties), or specialized pharma academies—not finance-oriented ones. If this refers to a different specific "Banking University" (e.g., in another country), provide more details for clarification! 38 web pages Tu Youyou's artemisinin discovery Peking University pharma research Sorry type 8 meant banking not banking Searching the web 39 results No, even correcting the typo to "type 8" (likely referring to a classification in Chinese higher education or related contexts), institutions commonly associated with "banking" or finance/economics universities in China—such as those categorized under the Ministry of Education's "Finance and Economics" (财经类) category—do not have notable strengths in the histories or fields we've discussed: chemistry, pharmacology, pharmaceutical innovation, biotech, or the legendary/modern Chinese figures in those areas (e.g., Shennong, Li Shizhen, Tu Youyou). Understanding "Type 8" in Context From Chinese university classifications (by the Ministry of Education): Universities are grouped into categories like "Finance and Economics" (财经类), "Medicine and Pharmacy" (医药类), "Comprehensive" (综合类), etc. "Finance and Economics" institutions (often what people mean by "banking universities") focus on accounting, finance, banking, economics, international trade, and business-related disciplines. Examples include: Shanghai Lixin University of Accounting and Finance (上海立信会计金融学院, frequently linked to banking heritage via its origins as Shanghai Banking School/Finance University). Central University of Finance and Economics (CUFE). University of International Business and Economics (UIBE). Dongbei University of Finance & Economics. Others like Tianjin University of Finance and Economics or Guangdong University of Finance & Economics (sometimes tagged in rankings or lists). These are specialized public colleges/universities emphasizing financial talent cultivation for China's banking sector, economic policy, auditing, and related fields—no evidence of departments, research programs, or historical contributions in chemistry, pharmacology, pharma R&D, medicinal chemistry, or biotech. Why No Overlap with the Discussed Histories Core Focus: These universities excel in producing professionals for banks (e.g., People's Bank of China ties historically), financial markets, accounting (e.g., Shanghai Lixin traces to Pan Xulun, "Father of Modern Accounting in China"), and economic development. Their strengths lie in applied economics, fintech, international finance, and business—not STEM fields like drug discovery, herbal pharmacology, or biopharma innovation. No Relevant Programs or Research: Searches show zero notable output, rankings, or collaborations in pharmacology/toxicology, chemistry, biotech, or oncology-related AI/drug development. China's leaders in those areas are: Peking University, Tsinghua University, Fudan University, Shanghai Jiao Tong University (top for pharmacology/toxicology globally). China Pharmaceutical University (Nanjing, specialized in pharma). Institutions tied to biotech hubs like Beijing-Tianjin-Hebei or Shanghai (e.g., for AI-cancer tools like RuiPath or DAMO Academy collaborations). Historical Disconnect: No ties to TCM pharmacology heritage (ancient texts/compounds) or modern breakthroughs like artemisinin. Finance-oriented schools support economic infrastructure that indirectly aids biopharma (e.g., funding/investment in biotech firms), but they lack direct academic or research strengths in the scientific histories paralleled with AstraZeneca's chemical-to-pharma path. If "type 8" refers to something more specific (e.g., a particular ranking tier, VC shareholder type from studies, or another classification/code), or if it's a different institution altogether, clarify for a deeper check. Otherwise, for chemistry/pharma/biotech histories and strengths in China, look to comprehensive or medicine/pharmacy-category universities—not banking/finance ones. 39 web pages China Pharmaceutical University details Tu Youyou biography Oh dear type 8 should be typo and wanted to understand if manning still contributed to chemicals foundational intelligence and cancer trsearch Searching the web 35 results Yes, several individuals and entities named Manning continue to make significant contributions to foundational aspects of chemistry (e.g., medicinal/radiochemistry, molecular probes), intelligence (in the sense of foundational scientific understanding or emerging AI applications in research), and especially cancer research as of January 30, 2026. These are active, ongoing efforts in academia and biotech, often building on chemical principles for drug discovery, imaging, and targeted therapies.No single "Manning University" exists as an institution with these strengths (as clarified earlier), but the name "Manning" is prominently tied to high-impact work in these areas through people and institutes. Key Ongoing Contributions Paul and Diane Manning Institute of Biotechnology (at the University of Virginia, UVA) This is a major, philanthropically funded biotech hub (launched via a $100 million donation from Paul Manning, a healthcare entrepreneur and UVA Health System Board chair). Focus: Research, development, commercialization, and manufacturing of advanced therapies like cellular therapy, gene therapy, immunotherapies, nanotechnology, and drug delivery. Strengths in cancer research: Explicit emphasis on leveraging UVA's existing expertise in oncology (alongside neuroscience and immunology). The institute is producing discoveries as a "foundation" for new cancer treatments and cures, with virtual operations already yielding results. Construction milestones reached in 2025, aiming for full completion around 2027 to become a national hub attracting pharma/biotech partners. Ties to chemistry foundational intelligence: Involves cutting-edge chemical and molecular approaches in drug delivery and biologics, building foundational knowledge for next-gen medicine. H. Charles Manning (Henry Charles Manning, Ph.D.) – MD Anderson Cancer Center Professor in the Department of Cancer Systems Imaging; leads efforts in radiochemistry, medicinal chemistry, and PET imaging tracers/therapies. Contributions: Develops chemical probes and radiopharmaceuticals to visualize and target molecular events in cancer (e.g., metabolism, glutamine transport, theranostics for colorectal and other cancers). His lab translates imaging/chemical tools for precision oncology, with recent publications (e.g., 2025 in Pharmaceuticals and Clinical Cancer Research) on fluoride-based reactions, compatibility in radiopharma, and more. Ongoing impact: Funded projects (e.g., via Project Cure CRC) for theranostic pairs in colorectal cancer; high citation count (thousands) and active clinical translation. Brendan Manning – Harvard T.H. Chan School of Public Health Professor and chair (Department of Molecular Metabolism); focuses on PI3K-mTOR signaling pathways linking nutrient sensing, metabolism, and cancer. Contributions: Defines how these networks drive cancer metabolism, with implications for therapies in oncology, diabetes, and aging. Longstanding NCI Outstanding Investigator Awards; research uncovers foundational mechanisms (e.g., TSC-mTOR connections) that inform drug targeting in tumors. Other notable Mannings in related fields: Maurice Manning (University of Toledo): Peptide synthesis for receptors relevant to diseases, including cancer contexts. Thomas Manning (Valdosta State University): Chemistry professor with work on anticancer drugs and related innovations. These efforts align with broader trends: using chemical foundations (probe design, synthesis) to build intelligence (deeper molecular understanding, sometimes enhanced by AI in imaging/analysis) for cancer breakthroughs. No direct link to AstraZeneca or prior China/AI-oncology discussions, but they represent active U.S.-based advancements in the same domain (targeted cancer therapies via chemistry/biotech). If this refers to a specific "Manning" (e.g., a person, company, or different context), more details would help refine! 35 web pages Details on H. Charles Manning's radiochemistry AI in cancer imaging applications Oh dear manning should read nanjing Searching the web 29 results Yes, Nanjing University (NJU) in China has substantial and ongoing strengths in the areas we've discussed: chemistry (including foundational aspects), pharmacology/pharmaceutical sciences, biotech, and cancer research. It contributes significantly to "foundational intelligence" (deep scientific understanding, molecular mechanisms, and innovative tools) in these fields, often through state-of-the-art labs, high-impact publications, and interdisciplinary work that builds on China's historical pharmacology heritage (e.g., TCM-inspired discoveries like artemisinin).While China Pharmaceutical University (CPU) in Nanjing is the national leader in pharmacology and pharmaceutical sciences (e.g., ranked #1 domestically in pharmacy, top globally in pharmacology/toxicology and medicinal chemistry per US News, CWUR, and ESI rankings as of 2025–2026), NJU excels as a comprehensive top-tier university with world-class strengths in chemistry and related biotech/pharma areas. Key Strengths at Nanjing University Chemistry: Ranked #12 globally (US News Best Global Universities, with an overall score of 88.7), including strong research reputation (#65 globally, #16 regionally) and high publication output. NJU hosts the State Key Laboratory of Coordination Chemistry (the first inorganic chemistry research institute in China, est. 1978), focusing on molecular design, synthesis, and functional materials—foundational for drug discovery and advanced chemistry applications. Pharmacology, Toxicology, and Pharmaceutics: Ranked in the global top tiers (e.g., #105–139 in SCImago and US News categories), with active contributions via the State Key Laboratory of Pharmaceutical Biotechnology (61 faculty members, 54 principal investigators). This lab drives research in drug targets, biologics, and biotech innovations. Biotech and Life Sciences: Strong departments in Biotechnology and Pharmacy, Biology, and the School of Life Sciences. NJU integrates biotech with chemistry for areas like nanomedicine, biosensors, and molecular engineering. Cancer Research: NJU contributes through chemical biology, nanotechnology for tumor targeting (e.g., chemodynamic therapy via Fenton/Fenton-like chemistry), bioorthogonal nanoengineering for tumor models, biosensors for cancer detection, and AI-augmented biology (e.g., non-coding RNA, TCM integration, and AI in diagnostics). Faculty like those in the School of Chemistry and Chemical Engineering work on cancer inhibitors, imaging probes, and precision oncology tools. Collaborations extend to AI in oncology (e.g., via conferences like Nature's AI Augmented Biology hosted/co-organized by NJU). Ties to Historical Pharmacology Heritage Nanjing has played a role in key milestones, such as meetings during the 523 Project (which led to artemisinin's discovery by Tu Youyou). While Tu Youyou was affiliated with Beijing-based institutions and the China Academy of Traditional Chinese Medicine, project progress was shared at key Nanjing meetings (e.g., 1972 presentations). NJU's modern work builds on this legacy by fusing TCM-inspired approaches with cutting-edge chemistry and biotech (e.g., natural product-derived therapies, molecular simulations for cancer inhibitors). Comparison to Nearby Institutions China Pharmaceutical University (CPU, also in Nanjing): Dominates pure pharma/pharmacology (A+ discipline rating, global top in medicinal chemistry and TCM-pharma integration)—more specialized in drug development pipelines. NJU: Broader, foundational strengths in chemistry and interdisciplinary biotech, making it a powerhouse for "foundational intelligence" (e.g., molecular mechanisms, novel probes, and AI/biology fusion) that underpins cancer and pharma advances. In summary, Nanjing University is a major contributor to these fields globally and in China, with active research that advances foundational chemistry knowledge toward cancer breakthroughs—aligning well with the historical and modern themes (from ancient TCM empiricism to AI-driven oncology) we've explored. If you're interested in specific labs, faculty, or recent papers, I can dive deeper! 29 web pages Recent NJU cancer research papers Tsinghua University biotech strengths Is nanjing top 12 in any other subjects Searching the web 38 results Yes, Nanjing University (NJU) ranks in the global top 12 (or equivalent high tiers) in several subjects beyond chemistry, based on major 2025–2026 rankings from sources like US News & World Report, Times Higher Education (THE), QS, and others. While its #12 spot in chemistry (US News) is strong, NJU excels particularly in STEM and interdisciplinary fields, reflecting its research-intensive profile.Here are key examples where NJU achieves top-tier global rankings (focusing on top 12 or close equivalents like top 50–60 in broad categories): Artificial Intelligence — #41 globally (US News Best Global Universities 2025–2026). This places it among the world's elite in AI research and applications. Computer Science — #60 globally (THE World University Rankings by Subject 2026). Engineering — =52 globally (THE 2026), often in the top 50–60 range across Asia-focused lists. Education Studies — =54 globally (THE 2026). Geology (or Earth Sciences-related) — =22 globally (QS World University Rankings by Subject 2025, with strong performance continuing into 2026 cycles). Other high rankings include: Life Sciences: #73 (THE 2026). Overall strong performance in Natural Sciences, Physics, Materials Science, and Environmental Sciences (frequently top 100 globally across ARWU/ShanghaiRanking and US News, with NJU in China's top 10 universities). NJU consistently ranks in the global top 100 overall (e.g., #86 in US News 2025–2026, #62 in THE 2026, #=103 in QS 2026), with particular depth in physical sciences, engineering, and emerging tech like AI—aligning well with China's push in these areas. It does not typically crack the absolute top 10–12 in non-STEM fields (e.g., Arts & Humanities at 151–175 in THE), but its STEM strengths make it a powerhouse comparable to other elite Chinese institutions like Tsinghua or Peking in select domains.These rankings evolve annually based on metrics like research output, citations, and international collaboration. For the most precise/current details, refer to official sites like usnews.com, timeshighereducation.com, or topuniversities.com. If you're interested in a specific subject or ranking source, let me know! 38 web pages Compare NJU to Tsinghua rankings Peking University rankings see part 3

[chris macrae]

Going back to chemistry who are global top 20 according to ranking that put nanjing 12 Searching the web 23 results Yes, the ranking that places Nanjing University (NJU) at #12 globally in Chemistry is the US News & World Report Best Global Universities for Chemistry (2025–2026 edition, released around mid-2025). This subject-specific ranking evaluates universities based on factors like global and regional research reputation, publications, citations, international collaboration, and normalized citation impact in chemistry.NJU achieves an overall subject score of 88.7 in this ranking, reflecting its strong output from the School of Chemistry and Chemical Engineering, including the State Key Laboratory of Coordination Chemistry. Global Top 20 in US News Best Global Universities for Chemistry (2025–2026) While exact positions 1–11 are not fully detailed in public snippets (US News lists are often paywalled or partial in free views, with top spots typically dominated by institutions like Tsinghua, Harvard, Stanford, MIT, UC Berkeley, etc.), the pattern from consistent sources and cross-references shows heavy representation from Chinese and US universities in the upper echelons due to high-volume, high-impact research.Typical top performers in this ranking (based on recent cycles and partial data): 1–5: Often Tsinghua University (China, frequently #1 or top 3), Harvard University (US), Stanford University (US), MIT (US), University of Chinese Academy of Sciences (China). 6–10: Institutions like Peking University (China), University of Science and Technology of China (USTC, China), Northwestern University (US), Nanyang Technological University (Singapore), etc. 11+: Leading to NJU at #12.Chinese universities dominate the top 20 in this specific US News Chemistry ranking due to massive research output in areas like materials chemistry, catalysis, and coordination chemistry—NJU fits right in this surge.For comparison in other major rankings (where NJU is strong but not exactly #12): QS World University Rankings by Subject: Chemistry 2025 — NJU ranks around #25 (score 81.7), with top spots like Harvard (#1), MIT, Stanford, UC Berkeley, Oxford, etc. Times Higher Education (THE) Physical Sciences 2026 (includes chemistry) — NJU at =31 (score 79.2), with top like Harvard, Stanford, MIT, Princeton. ShanghaiRanking (ARWU) Chemistry — NJU often top 50–100, with Harvard, Stanford, MIT leading. The US News ranking is particularly favorable to NJU's profile due to its emphasis on publication volume and citation metrics in chemistry. If you'd like the full top 20 list, I recommend checking the official US News site directly (usnews.com/education/best-global-universities/chemistry), as it's the definitive source for this specific placement. Let me know if you want details on another ranking or subject! 23 web pages NJU's coordination chemistry research Tsinghua University chemistry ranking Are any British universities in global top 20 chemistry Searching the web 29 results Yes, several British universities rank in the global top 20 for Chemistry across major international rankings as of early 2026 (data from 2025–2026 cycles). The exact placement varies by methodology—US News emphasizes research output/citations, QS focuses on academic reputation/employer views, and Times Higher Education (THE) covers Physical Sciences broadly (including chemistry). In the US News Best Global Universities for Chemistry (the ranking placing Nanjing University at #12) British universities perform strongly but do not crack the absolute top 10–12 in this specific list, which is heavily dominated by US and Chinese institutions due to high publication volumes. However, top UK ones appear in the broader top tiers: University of Cambridge and University of Oxford are typically the highest-ranked British ones (often in the global top 20–30 range based on cross-references and UK-specific sub-rankings). Imperial College London, University of Manchester, and University College London follow closely. No British university is confirmed in the exact top 12 here, but Cambridge/Oxford are prominent globally in chemistry research reputation. Stronger Showings in Other Major Rankings British institutions shine brighter in QS and THE, where historical prestige, research quality, and international outlook boost them: QS World University Rankings by Subject: Chemistry 2025 University of Cambridge — #3 globally (score 94.2) Other top British ones: Oxford (typically #5–10), Imperial College London (top 10–15 range). Top 20 includes at least 2–3 UK universities, with Cambridge consistently elite. Times Higher Education (THE) Physical Sciences 2026 (encompassing chemistry, physics, etc.) University of Oxford — #8 globally (score 94.8) University of Cambridge — Often #7 or similar in recent cycles (top 10). These place multiple British universities in the global top 10–20 for physical sciences/chemistry-related fields. In summary, yes—especially Cambridge and Oxford frequently rank in the global top 20 (and often top 10) for chemistry in prominent rankings like QS and THE. In the specific US News Chemistry ranking (where Nanjing is #12), UK strengths are present but lower in the absolute top due to the metric focus on volume-heavy research from Asia/US. For the most up-to-date full lists, check usnews.com (for Chemistry), topuniversities.com (QS), or timeshighereducation.com (THE). If you want details on a specific ranking or university, let me know! 29 web pages Compare Oxford and Cambridge Chemistry Top US Chemistry Universities Around world which are astra zeneca top university partners especially asia Searching the web 40 results AstraZeneca maintains extensive university partnerships worldwide, with a strong emphasis on academic collaborations for R&D, talent development, clinical research, and innovation ecosystems. Globally, its most prominent and longstanding partners are often in the UK (due to its Cambridge headquarters and Discovery Centre) and the US, but Asia (particularly China, Hong Kong, Singapore, Japan, South Korea, and India) has grown significantly, driven by AstraZeneca's major investments (e.g., $15 billion in China through 2030) and focus on accessing Asian innovation in oncology, cardiovascular, respiratory, and emerging areas like AI/biotech. Top Global University Partners (Overall Highlights) AstraZeneca frequently highlights these as strategic or high-impact: University of Cambridge (UK) — Flagship partner for over a decade; co-located at Cambridge Biomedical Campus; joint research, talent programs, and ecosystem building (e.g., recent extensions to Beijing collaborations). University of Oxford (UK) — Ties via COVID vaccine (AZD1222) development and ongoing ecosystem links. University of Virginia (US) — Recent Master Research Collaboration Agreement for pre-clinical innovation (2026). Others: Johns Hopkins (US, e.g., scholars program via legacy MedImmune), University of Glasgow (UK, climate/health education), King's College London (UK, ecosystem ties). Top University Partners in Asia (Especially Strong Focus) AstraZeneca's Asia partnerships emphasize China (its largest market outside the US/UK), with growing ties in Hong Kong, Singapore, Japan, South Korea, India, and others. Key ones include: China (heaviest footprint, with R&D centers in Beijing/Shanghai and collaborations with 500+ hospitals/universities): University of Cambridge + Beijing ecosystem — Tripartite agreement (2025–2026) linking Cambridge, AstraZeneca, and Beijing municipal parties (Beijing Science and Technology Commission, Beijing Economic-Technological Development Area/BioPark) for life sciences innovation, education, and bilateral exchanges. Historical/ongoing: Fudan University (cardiovascular research), Tianjin Medical University (cardiovascular), Shenzhen University Health Science Center (chronic kidney disease). Broader: Ties to Chinese Academy of Sciences, Southern University of Science and Technology, Guangzhou University of Chinese Medicine (e.g., regenerative medicine/stem cells via events/partners). Hong Kong: Hong Kong University of Science and Technology (HKUST) — MoU signed in 2025 to advance life sciences, healthcare R&D, and innovation translation. Singapore: National University Health System (NUHS)/National University of Singapore — Part of Global Health Innovation Network (with Sahlgrenska University Hospital, Ericsson; formalized 2024) for clinical experience, resources, and healthcare innovation. Japan: Keio University Medical School — Longstanding oncology clinical projects and collaborations. India: SASTRA Deemed University (Thanjavur) — MoU (2023 onward) for curriculum development in clinical research & development. Other Asia: Thailand: Faculty of Medicine Siriraj Hospital (MoU for clinical research enhancement, 2024). South Korea: Indirect via AI diagnostics (e.g., AIVIS partnership with AstraZeneca Korea). Broader: A.Catalyst Network hubs in Asia (e.g., China iCampus, Malaysia) support academic/startup collaborations. These Asia partnerships align with AstraZeneca's strategy to tap local talent, data, and innovation (e.g., TCM integration, AI-oncology tools) while bridging to global hubs like Cambridge. China stands out as the priority region, with ecosystem models (e.g., Beijing BioPark mirroring Cambridge) and recent high-level announcements. For the latest specifics, AstraZeneca's partnering site or press releases provide ongoing updates. If you'd like details on a particular country or partnership, let me know! 40 web pages Details on Fudan University collaboration Pfizer university partnerships Does astra zeneca have any partnerships with medical colleges supported by li.ka shing Searching the web 48 results Yes, AstraZeneca has indirect but notable connections to medical colleges/institutions supported by the Li Ka Shing Foundation (LKSF), primarily through shared research ecosystems and facilities rather than direct bilateral partnerships with the foundation itself. Li Ka Shing has been a major philanthropist in medical education and research, funding facilities like the Li Ka Shing Faculty of Medicine at the University of Hong Kong (HKU), the Li Ka Shing Faculty of Medicine-affiliated centers, and similar initiatives at other institutions (e.g., Shantou University Medical College in China, which received substantial LKSF support for its medical programs). Key Connections and Examples University of Cambridge / Cancer Research UK Cambridge Institute (housed in the Li Ka Shing Centre): AstraZeneca has longstanding, high-profile partnerships with the University of Cambridge and the Cancer Research UK Cambridge Institute for oncology research, including pre-clinical/clinical projects on tumor mutations, targeted therapies (e.g., prostate and pancreatic cancers), and the CRUK-AstraZeneca Functional Genomics Centre (using CRISPR for drug discovery). The institute is physically located in the Li Ka Shing Centre on the Cambridge Biomedical Campus—a state-of-the-art facility funded by the Li Ka Shing Foundation (via Hutchison Whampoa/Li Ka Shing's contributions), along with other donors. This creates an indirect link: AstraZeneca's collaborations occur within a building and ecosystem supported by LKSF philanthropy. Recent activities (e.g., 2025 updates on early targeted therapy findings) continue this partnership. Hong Kong Institutions (e.g., HKU Li Ka Shing Faculty of Medicine): No direct AstraZeneca-LKSF or AstraZeneca-HKU Faculty of Medicine partnership is evident in major announcements. However, AstraZeneca Hong Kong actively engages with Hong Kong's life sciences ecosystem, including MoUs with nearby institutions like HKUST (Hong Kong University of Science and Technology) for AI/ML in life sciences and healthcare innovation (signed 2025). HKU's Li Ka Shing Faculty has been referenced in AstraZeneca-related contexts (e.g., studies on youth health in AstraZeneca's Young Health Programme, or publications involving COVID-19 vaccine data), but these are academic outputs rather than formal partnerships. AstraZeneca supports broader Hong Kong initiatives (e.g., via its Global R&D China Hong Kong Centre and A.Catalyst Network hub), which align with LKSF-backed advancements in medical tech (e.g., donations for histotripsy liver cancer treatment at HKU in 2024), though no joint projects are directly tied. Other Li Ka Shing-Supported Entities: Shantou University Medical College (heavily funded by LKSF for reforms and modernization): No documented AstraZeneca partnership. Broader LKSF initiatives (e.g., at UC Berkeley's Innovative Genomics Institute or other global centers): AstraZeneca has collaborated with IGI on CRISPR for cancer drug discovery (extended in 2018), but LKSF's role is as an early supporter/funder rather than a direct partner in those specific deals. Overall, the strongest link is through the Li Ka Shing Centre at Cambridge, where AstraZeneca's active oncology collaborations with the University of Cambridge/CRUK occur in a facility bearing LKSF's name and funding. This reflects AstraZeneca's strategy of partnering with top academic centers in ecosystems supported by major philanthropists like Li Ka Shing. No evidence of direct, exclusive partnerships with LKSF itself or its named medical colleges (e.g., no joint funding, co-developed programs, or announcements specifically naming LKSF medical entities as partners). For the latest developments, AstraZeneca's partnering updates or LKSF's project lists are good sources. If you're referring to a specific college or region, more details could help narrow it! 48 web pages Details on Cambridge Centre research Li Ka Shing philanthropy overview Think Harder No file chosen